Connect
MJA
MJA

Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus

N Wah Cheung, Jennifer J Conn, Michael C d’Emden, Jenny E Gunton, Alicia J Jenkins, Glynis P Ross, Ashim K Sinha, Sofianos Andrikopoulos, Stephen Colagiuri and Stephen M Twigg
Med J Aust 2009; 191 (6): 339-344.
  • N Wah Cheung1,2
  • Jennifer J Conn3
  • Michael C d’Emden4
  • Jenny E Gunton1,2,5
  • Alicia J Jenkins6
  • Glynis P Ross7,8
  • Ashim K Sinha9
  • Sofianos Andrikopoulos10
  • Stephen Colagiuri11
  • Stephen M Twigg2,7

  • 1 Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW.
  • 2 Department of Medicine, University of Sydney, Sydney, NSW.
  • 3 Royal Melbourne Hospital, Melbourne, VIC.
  • 4 Royal Brisbane and Women’s Hospital, Brisbane, QLD.
  • 5 St Vincent’s Clinical School, University of New South Wales, Sydney, NSW.
  • 6 Department of Medicine, University of Melbourne, St Vincent’s Hospital, Melbourne, VIC.
  • 7 Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW.
  • 8 Bankstown–Lidcombe Hospital, Sydney, NSW.
  • 9 Cairns Base Hospital, Cairns, QLD.
  • 10 Department of Medicine, University of Melbourne, Heidelberg Repatriation Hospital, Melbourne, VIC.
  • 11 Boden Institute of Obesity, Nutrition and Exercise, University of Sydney, Sydney, NSW.


Acknowledgements: 

We thank Professor Don Chisholm, Professor Peter Colman and Associate Professor Jeff Flack for reviewing this position statement and providing valuable comments.

Competing interests:

Wah Cheung received a travel grant from GlaxoSmithKline and another from Eli Lilly to attend conferences. Jennifer Conn received travel grants from Novo Nordisk. Michael d’Emden received speaker fees, honoraria for attending advisory board meetings and support to attend meetings of the Australian Diabetes Association and European Association for the Study of Diabetes from Eli Lilly, Novo Nordisk, Novartis, Sanofi-Aventis, Bayer and Merck Sharpe & Dohme. Jenny Gunton received speaker fees from Eli Lilly. Alicia Jenkins is a member of the Merck Diabetes Advisory Board. She is a chief investigator of an investigator-initiated study, funded by Medtronic, about use of glucose sensor-augmented pumps in type 1 diabetes; she has not received a salary for this work. Glynis Ross received travel grants from Novo Nordisk to attend meetings, and speaker fees from Medtronic. Ashim Sinha has received travel grants and speaker fees from Eli Lilly, Novo Nordisk, GlaxoSmithKline and Sanofi-Aventis. He is also on an advisory board for Sanofi-Aventis. Stephen Twigg is a paid consultant for the advisory boards of Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi-Aventis. He receives speaker fees from Merck Sharp & Dohme, and meeting organiser fees from the Eli Lilly Meeting Faculty. He receives travel assistance to attend meetings from Sanofi-Aventis, GlaxoSmithKline and Novo Nordisk.

  • 1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
  • 2. Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
  • 3. Turner RC, Holman RR, Stratton IM, et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
  • 4. Colagiuri S, Dickinson S, Girgis S, Colagiuri R. Evidence based guideline for blood glucose control in type 2 diabetes. Public consultation draft, August 2008. http://www.diabetesaustralia.com.au/PageFiles/7852/FINALBLOODGLUCOSEpublicconsultationdocumentAugust2008.pdf (accessed Aug 2009).
  • 5. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
  • 6. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
  • 7. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
  • 8. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
  • 9. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
  • 10. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431.
  • 11. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
  • 12. Wright AD, Cull CA, Macleod KM, Holman RR. Hypoglycaemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006; 20: 395-401.
  • 13. White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy in the risk of retinopathy complications in patients with type 1 diabetes mellitus. Arch Ophthalmol 2008; 126: 1707-1715.
  • 14. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. JAMA 2003; 290: 2159-2167.
  • 15. Martin CL, Waberski B, Albers J, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340-344.
  • 16. Nathan DM, Cleary PA, Backlund JYC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
  • 17. Guerin A, Nisenbaum R, Rav JG. Use of maternal GHb concentration to estimate the risk of congenital anomaly in the offspring of women with prepregnancy diabetes. Diabetes Care 2007; 30: 1920-1925.
  • 18. Clausen TD, Mathiesen E, Ekbom P, et al. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 2005; 28: 323-328.
  • 19. The Diabetes Control and Complications Trial Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996; 174: 1343-1353.
  • 20. McElduff A, Cheung NW, McIntyre HD, et al. The Australasian Diabetes in Pregnancy Society consensus guidelines for the management of type 1 and type 2 diabetes in relation to pregnancy. Med J Aust 2005; 183: 373-377. <MJA full text>
  • 21. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes — STENO 2. N Engl J Med 2008; 358: 580-591.
  • 22. Turner R, Holman R, Stratton I, et al. Tight blood-pressure control and risk of macrovascular and microvascular complications in patients with type 2 diabetes: (UKPDS 38). Lancet 1998; 352: 837-853.
  • 23. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
  • 24. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
  • 25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
  • 26. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.